Open Access policy

All current published content in Acta Oncologica is published with immediate open access, which means that you as a user do not need to pay or register to read content. Open Access publication implies global dissemination, increased impact and an optimized potential for citation and outreach beyond academia. Articles are published immediately upon approval of the final proof and payment of the publication fee. All articles are assigned a DOI number (Digital Object Identifier).

Authors of content published in Acta Oncologica retain copyright to their works. Articles are published under the terms of a Creative Commons license CC-BY-NC 4.0, which permits use, downloading, distribution, linking to, and reproduction in any medium, provided the original work is properly cited. This license allows for the non-commercial reuse of the published paper so long as the published paper is fully attributed.

Authors who are required by their funders or Open Access agreements to publish their articles under a Creative Commons Attribution (CC-BY 4.0 licence) license have the option of doing so upon request. This license permits the reuse for commercial purposes but still requires that the article is fully attributed.  All commercial requests to re-use the article in whole or in part will be handled by the Acta Oncologica Foundations through contact to Any permission fees will be retained by this organization. For the purposes of these terms, “commercial use” means use in any manner that is primarily intended for or directed toward commercial advantage or monetary compensation, including but not limited to provision or distribution (including by way of hyperlink) of the article (including any abstract, figures or tables) in any format. For further information on the commercial use of published papers please contact us.

Authors are encouraged to deposit the final published version of their article for self-archiving (author's personal website) and/or archiving in an institutional archive immediately after publication.

When publishing articles in Acta Oncologica, the author(s) grant first publication rights to Medical Journals Sweden. In consideration of the publication of the article, the authors grant Acta Oncologica the licence to 1) publish, reproduce, distribute, display and store the article worldwide in all forms, formats and media now known or as developed in the future, including print, electronic and digital forms, and 2) to translate the article into other languages, create adaptations, summaries or extracts of the article. Please note that authors are themselves responsible for obtaining permission for reproducing copyrighted material from other sources.

For content in Acta Oncologica, Volumes 1-62 license and copyright information is stipulated in each article.